Type-specific human papillomavirus distribution in invasive cervical carcinomas in Paraguay. A study of 432 cases

Journal of Medical Virology

Volumn 84, Issue 10, 2012, Pages 1628-1635

  Kasamatsu, Elena ^a   Cubilla, Antonio L ^b   Alemany, Laia ^c,d   Chaux, Alcides ^b,e   Tous, Sara ^c   Mendoza, Laura ^a   Paez, Malvina ^a   Klaustermeier, Jo Ellen ^c,d   Quint, Wim ^f   Lloveras, Belen ^c,g   de Sanjose, Silvia ^c,d   Muñoz, Nubia ^c   Bosch, Francisco Xavier ^c  

^a Instituto de Investigaciones en Ciencias de la Salud Universidad Nacional de Asuncion   (Paraguay)

^b Pathology and Research Institute   (Paraguay)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f DDL DIAGNOSTIC LABORATORY   (Netherlands)

^g HOSPITAL DEL MAR   (Spain)

Author keywords

Cervical cancer; HPV genotypes; Paraguay; Trends

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INVASION; CANCER SCREENING; DNA HYBRIDIZATION; ENZYME IMMUNOASSAY; GENOTYPE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PARAGUAY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; VIRUS DETECTION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CERVIX UTERI; CROSS-SECTIONAL STUDIES; DNA PRIMERS; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; NUCLEIC ACID HYBRIDIZATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PARAGUAY; POLYMERASE CHAIN REACTION; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 84865556729     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23373     Document Type: Article

References (33)

1. Almonte M, Murillo R, Sánchez GI, Jerónimo J, Salmerón J, Ferreccio C, Lazcano-Ponce E, Herrero R. 2010. Nuevos paradigmas y desafíos en la prevención y control del cáncer de cuello uterino en América Latina. Salud Pública Mex 52:544-549.
2. Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. 1995. International biological study on cervical cancer (IBSCC) Study Group. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. J Nat Cancer Inst 87:796-802.
3. Castellsagué X, de Sanjosé S, Aguado T, Louie KS, Bruni L, Muñoz J, Diaz M, Irwin K, Gacic M, Beauvais O, Albero G, Ferrer E, Byrne S, Bosch FX. 2007. HPV and cervical cancer in the World. 2007 report. WHO/ICO Information Centre on HPV and cervical cancer (HPV Information Centre). Vaccine 25:C100.
4. Cubilla AL, Lloveras B, Alejo M, Clavero O, Chaux A, Kasamatsu E, Velazquez EF, Lezcano C, Monfulleda N, Tous S, Alemany L, Klaustermeier J, Muñoz N, Quint W, de Sanjose S, Bosch FX. 2010. The basaloid cell is the best tissue marker for human papillomavirus in invasive penile squamous cell carcinoma: A study of 202 cases from Paraguay. Am J Surg Pathol 34:104-114.
5. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Menéndez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, Puras A, Llave CL, Tzardi M, Agorastos T, Garcia-Barriola V, Clavel C, Ordi J, Andújar M, Castellsagué X, Sánchez GI, Nowakowski AM, Bornstein J, Muñoz N, Bosch FX. 2010. Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncol 11:1048-1056.
6. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin DM. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 1276:2893-2917.
7. Hildesheim A, Berrington de Gonzalez A. 2006. Etiology and prevention of cervical adenocarcinomas. J Nat Cancer Inst 98:292-293.
8. Kasamatsu E, Ascurra M, Hullin CH, Nakajima T, Shozawa T. 1996. Detection and typing of human papillomavirus DNA in invasive squamous cell carcinoma of the cervix by polymerase chain reaction and its correlation with histopathological findings. An Fac Cienc Méd 29:317-333.
9. Kleter B, van Doorn LJ, Ter Schegget J, Schrauwen L, Van Krimpen K, Burger M, ter Harmsel B, Quint W. 1998. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol 153:1731-1739.
10. Kleter B, van Doorn LJ, Schrauwen L, Molijn A, Sastrowijoto S, ter Schegget J, Lindeman J, ter Harmsel B, Burger M, Quint W. 1999. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 37:2508-2517.
11. Lazcano-Ponce E, Salmeron-Castro J, Garzía-Carrancá A, Aranda-Flores C, Madrid-Marina V, Gomez-Altamirano CM, Martinez Montañez O. 2009. Recommendations for the definition of a policy on vaccination against papillomavirus in Mexico. Strategic advisory group of experts of the world health organization. Salud Publica Mex 51:336-341.
12. Lazcano-Ponce E, Lörincz AT, Salmerón J, Fernández I, Cruz A, Hernández P, Mejía I, Hernández-Avila M. 2010. A pilot study of HPV DNA and cytology testing in 50, 159 women in the routine Mexican Social Security Program. Cancer Causes Control 21:1693-1700.
13. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner R, Apter D, Naud P, Salmeron J, Chow S, Kitchener H, Teixeira JC, Hedrik J, Limson G, Szarewski A, Romanowski B, Aoki F, Schwarz TF, Poppe WAJ, De Carvlho NS, Germar MJV, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Descamp D, Struyf F, Dubin G, for the HPV PATRICIA Study Group. 2011. Overall efficacy of HPV-16/18AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4 year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13:89-99.
14. Mariani L, Monfulleda N, Alemany L, Vizza E, Marandino F, Vocaturo A, Benevolo M, Quirós B, Lloveras B, Klaustermeier JE, Quint W, de San José S, Bosch FX. 2010. Human papillomavirus prevalence and type-specific relative contribution in invasive cervical cancer specimens from Italy. BMC Cancer 10:259-266.
15. Mendoza LP, Arbiza J, Páez M, Kasamatsu E, Castro A, Jiménez G, Basiletti J, Gonzalez J, Mongelós P, Picconi MA. 2011. Distribution of human papillomavirus genotypes in Paraguayan women according to severity of cervical lesion. J Med Virol 83:1351-1357.
16. Muñoz N, Bosch FX, de San José S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meier CJ. 2003. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 384:518-527.
17. Muñoz N, Franco E, Herrero R, Andrus JK, de Quadros C, Goldie SJ, Bosch FX. 2008. Recommendations for cervical cancer prevention in Latin America and the Caribbean. Vaccine 26S:L96-L107.
18. Murillo R, Almonte M, Pereira A, Ferrer E, Gamboa OA, Jerónimo J, Lazcano-Ponce E. 2008. Cervical cancer screening programs in Latin America and the Caribbean. Vaccine 26S:L37-L48.
19. Murillo R, Molano M, Martínez G, Mejia JC, Gamboa O. 2009. HPV prevalence in Colombian women with cervical cancer: Implications for vaccination in a developing country. Inf Dis Obstetr Gynecol 2009:1-9.
20. Oh JK, Alemany L, Suh JI, Rha SH, Muñoz N, Bosch FX, Quint W, Lloveras B, Klaustermeier JE, de San José S, Shin HR. 2010. Type-specific human papillomavirus distribution in invasive cervical cancer in Korea, 1958-2004. Asian Pacific J Cancer Prev 11:993-1000.
21. Park KJ, Kiyokawa T, Soslow RA, Lamb CA, et al. 2011. Unusual endocervical adenocarcinomas: An immunohistochemical analysis with molecular detection of human papillomavirus. Am J Surg Pathol 35:633-646.
22. Parkin DM, Almonte M, Bruni L, Clifford G, Curado MP, Pineros M. 2008. Burden and trends of type-specific human papillomavirus infections and related diseases in the Latin America and Caribbean region. Vaccine 26S11:L1-L5.
23. Rolón PA, Smith JS, Muñoz N, Klug SJ, Herrero R, Bosch X, Llamosas F, Meier CJ, Walboomers JM. 2000. Human papillomavirus infection and invasive cancer in Paraguay. Int J Cancer 85:486-491.
24. Sankaranarayanan R, Nene BM, Shastri S, Jayant K, Muwonge R, Budukh A, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar MS, Rajeshwarkar R, Panse N, Dinshaw A. 2009. HPV screening for cervical cancer in rural India. N Engl J 360:1385-1394.
25. Schiffman M, Clifford G, Buonaguro FM. 2009. Classification of weekly carcinogenic human papillomavirus tpes: Addressing the limits of epidemiology and the borderline. Infect Agent Cancer 4:1-8.
26. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. 2007. Human papillomavirus type distribution in invasive cervical cancer and high-grade lesions: A meta-analysis update. Int J Cancer 121:621-632.
27. Usuibütün A, Alemany L, Kücükali T, Ayhanb A, Yüce K, de San José S, Font R, Lloveras B, Klaustermeier JE, Quint W, Muñoz N, Bosch FX. 2009. Human papillomavirus types in invasive cervical cancer specimens from Turkey. Int J Gynecol Pathol 28:541-548.
28. Vaccarella S, Franceschi S, Snijder PJF, Herrero R, Meijer CJLM, Plummer M. IARC HPV Prevalence Surveys Study Group. 2010. Concurrent infection with multiple Human papillomavirus types: Pooled analysis of the IARC HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev 19:503-510.
29. Vinokurova S, Wentzensen N, Kraus I, Kales R, Driesch C, Melssheimer P, Kisseljov F, Dürst M, Schneider A, von Knebel Doeberitz M. 2008. Type-dependent integration frequency of human papillomavirus genome in cervical lesions. Cancer Res 68:307-313.
30. Walboomers JM, Jacobs MV, Manos MM. et al. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19.
31. Wang SS, Sherman ME, Silverberg SG, Carreon JD, Lacey JV, Zaino R, Kurman RJ, Hildesheim A. 2006. Pathological characteristics of cervical adenocarinoma in a multi-center U.S.-based study. Gynecol Oncol 103:541-546.
32. Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmerón J, Chow S, Apter D, Kitchener H, Teixeira JC, Skinner SR, Jaisamrarn U, Limson G, Romanowski B, Aoki FY, Schwarz TF, Poppe WAJ, Bosch FX, Harper DM, Huh W, Hardt K, Zahaf T, Descamps D, Struyf F, Dubin G, Lehtinen M. for the HPV PATRICIA Study Group. 2011. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4 year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13:100-110.
33. WHO/ICO. HPV Information Centre. Human papillomavirus and related cancers, Paraguay. Summary report update 2010. Available at: www.who.int/hpvcentre